Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept
Open accessThe DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Abstract
Age-related macular degeneration (AMD) has become a major public health problem and a leading cause of blindness in industrialized nations. AMD results from the ageing eye's inability to metabolize and dispose completely of photoreceptor outer segments and other waste products. As a result, lipids, particularly apolipoproteins, accumulate within Bruch's membrane, leading to chronic ischemia and inflammation. The subsequent upregulation of inflammatory cytokines and growth factors, including vascular endothelial growth factor (VEGF), induces the growth of neovascular membranes from the choriocapillaris into the subretinal or subretinal pigment epithelium spaces. To counter this, intravitreally administered drugs (pegaptanib, bevacizumab, ranibizumab) that specifically target VEGF have become the standard treatment for exudative AMD. Aflibercept, a recently approved fusion protein, binds to all isoforms of both VEGF-A and placental growth factor with high affinity. Phase III trials showed that monthly or every other month injections of aflibercept prevent vision loss (fewer than 15 letters) in 95% of patients. Additionally, aflibercept injections every 4 or 8 weeks produce average vision gains of 6.9 letters to 10.9 letters, comparable with those achieved with monthly ranibizumab. After one year of regularly administered aflibercept injections, patients required an average of only 4.2 injections during the second year. Aflibercept promises to decrease the injection frequency required for many patients and appears to serve as an effective "salvage" therapy for patients who respond poorly to other anti-VEGF drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699 · cited 1×
“Angiopoietins regulate vascular integrity and also participate in pathologic neovascularization.(71) Angiopoietin-1 prevents leakage from the adult vasculature(72) whereas angiopoietin-2, which is upregulated in vascular endothelial cells by both hypoxia and VEGF,(73) enhances the vasoproliferative effects of VEGF.”
BackgroundRanibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Ranibizumab and bevacizumab for neovascular age-related macular degeneration
(2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102673 · Cited by 2,669
VEGF-Trap: A VEGF blocker with potent antitumor effects
Holash, J., Davis, S., Papadopoulos, N., Croll, S. D., Ho, L., Russell, M., Boland, P., Leidich, R., Hylton, D., Burova, E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172398299 · Cited by 1,691 · cited 1×
“5 pM), exceeding even that of the native receptors.(101) Whereas bevacizumab can simultaneously bind two VEGF dimers, and two ranibizumab molecules can bind one VEGF dimer, aflibercept tightly binds VEGF-A and placental growth factor dimers in a 1 to 1 ratio with a powerful “two-fisted grasp”.”
Hageman, G. (2001) · Progress in Retinal and Eye Research · doi:10.1016/s1350-9462(01)00010-6 · Cited by 1,265 · cited 1×
“Choroidal dendritic cells become activated by damaged RPE and oxidized protein and lipid in Bruch’s membrane.(54) Activated dendritic cells promote secretion of immune response modulators such as apolipoprotein E and vibronectin from the RPE and initiate an autoimmune response with production of antiretinal and anti-R…”
Drusen proteome analysis: an approach to the etiology of age-related macular degeneration
Crabb, J. W., Miyagi, M., Gu, X., Shadrach, K., West, K. A., Sakaguchi, H., Kamei, M., Hasan, A., Yan, L., Rayborn, M. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.222551899 · Cited by 1,208 · cited 1×
“40,41 Apoptotic cell death is further enhanced by the presence of advanced glycation end products which activate their receptors (RAGE) 42,43 and upregulate nuclear factor-kB.”
Regulation of matrix biology by matrix metalloproteinases
Mott, J. D., & Werb, Z. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.07.010 · Cited by 1,104 · cited 1×
“Matrix degradation causes the release of previously sequestered VEGF, thereby amplifying the proliferative drive.(97) VEGF breaks down the blood retinal barrier by phosphorylating tight junction proteins, forming transcellular vesicles, and creating fenestrations.”
Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies
Ambati, J., Ambati, B. K., Yoo, S. H., Ianchulev, S., & Adamis, A. P. (2003) · Survey of Ophthalmology · doi:10.1016/s0039-6257(03)00030-4 · Cited by 959 · cited 2×
“activators, and downregulating metalloproteinase inhibitors, VEGF degrades the intercellular matrix, thereby enabling endothelial cell migration.(76,96) Matrix degradation causes the release of previously sequestered VEGF, thereby amplifying the proliferative drive.”
Holz, F. G., Bindewald-Wittich, A., Fleckenstein, M., Dreyhaupt, J., Scholl, H. P. N., & Schmitz-Valckenberg, S. (2007) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2006.11.041 · Cited by 619
Cited by
Bakall, B., Folk, J. C., Boldt, H. C., Sohn, E. H., Stone, E. M., Russell, S. R., & Mahajan, V. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.017 · Cited by 229
Kiss, S., Grishanin, R., Nguyen, A., Rosario, R., Greengard, J. S., Nieves, J., Gelfman, C. M., & Gasmi, M. (2020) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2020.06.007 · Cited by 29
“PK profile of aflibercept following IVT-injected aflibercept recombinant protein evaluated in this study was similar to the published clearance rates of aflibercept after IVT administration in rabbits and cynomolgus monkeys,(38,39) and the half-life in vitreous humor (106 h) was very close to human vitreous humor rate…”
ResultKhanani, A. (2015) · Clinical Ophthalmology · doi:10.2147/opth.s88624 · Cited by 10
“The decision on which anti-VEGF to treat patients with is multifactorial and factors include availability, dosing schedule, recent trial data on efficacy and safety, and cost.(10) Based on the efficacy data from the VIEW trial, we decided to start fixed bimonthly aflibercept treatment in some of our patients in accord…”
Metadata
- Authors
- Stewart, M.
- Venue
- Clinical Ophthalmology
- Publisher
- Informa UK Limited
- Published
- 2012-07
- Volume
- 6
- Pages
- 1175
- ISSN
- 1177-5467 (ISSN-L)
- 1177-5483
- OpenAlex
- W2012225016
- Cited by
- 71
- References
- 15
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. https://app.cochat.ai/papers/10.2147/opth.s33372
- The paper
- Stewart, M. (2012). Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clinical Ophthalmology. https://doi.org/10.2147/opth.s33372
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.